# RESEARCH



# Is human herpesvirus 8 infection more common in men than in women? an updated meta-analysis



# Abstract

**Background** Clinically, most patients with Kaposi's sarcoma (KS) are male, and several direct and indirect mechanisms may underlie this increased susceptibility in men, Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is considered to be the primary etiological agent responsible for KS. Thus, we propose the hypothesis that men are more susceptible to HHV-8 infection, leading to a higher incidence of Kaposi's sarcoma among males. A meta-analysis was conducted to evaluate the association between gender and HHV-8 seropositivity in the general population.

**Methods** A comprehensive literature search was performed using 6 online databases: PubMed, EMBASE, Cochrane library, Web of Science, CNKI, and Wanfang. Studies published before March 15, 2023, were included.

**Results** In all, 33 articles including 41 studies were included in the meta-analysis. In the included adult population. men had a higher risk of HHV-8 infection than did women in adult populations from all over the world (odds ratio [OR]: 1.08, 95% confidence interval [CI]: 1.01–1.15), but no differences were found in child population from all over the world (OR: 0.90, 95% CI: 0.79–1.01). There was a significant difference in HHV-8 seroprevalence between men and women in sub-Saharan Africa (SSA) adult population (OR: 1.15, 95% CI: 1.05–1.26). However, no significant differences were observed in sub-Saharan Africa (SSA) child population (OR: 0.90, 95%CI 0.78–1.03). As for other continents, the results showed no significant difference, such as the Asian population (OR: 1.03, 95%CI: 0.92–1.16). or the European and American populations (OR 1.01, 95%CI 0.87–1.17).

**Conclusion** There was a slight gender disparity for HHV-8 infection in the adult population. Among the adult populations from SSA and globally, men were more likely to be infected with HHV-8 than were women. However, no statistical significance was observed in the child populations from SSA and globally. In the future, the inclusion of more standardized studies may strengthen the results of this study.

Keywords Kaposi's sarcoma, Human Herpesvirus 8, Seroprevalence

This work was presented at the 25th International Conference on KSHV and Related Agents; June 19 – June 23, 2023; Dar es Salaam, Tanzania.

\*Correspondence: Haibo Gong

gonghaibo2019@163.com

<sup>1</sup> Department of Dermatology, Henan Provincial People's Hospital; People's Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou, Zhengzhou, Henan 450003, China

# Background

Kaposi's sarcoma (KS) is a complex angioproliferative neoplasm that has attracted the attention of researchers and clinicians for decades [1, 2]. It primarily affects the skin of the extremities, face, trunk, external genitalia, and oropharyngeal mucosa. Lymph nodes and internal organs, most notably the respiratory and gastrointestinal tracts, are also often involved. It was first described and named by Moritz Kaposi, an Austro-Hungarian



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

dermatologist, in 1872 [3]. It is unclear why patients with various types of KS are predominantly male. Several factors such as hormonal factors, inherent differences in the immune system, and high-risk behaviors may contribute to this phenomenon. Kaposi's sarcoma-associated herpes virus (KSHV), also known as human herpesvirus 8 (HHV-8) is considered a crucial factor in the pathogenesis of KS [4, 5]. Whether HHV-8 seroprevalence differs between men and women and thus explains the male predominance of KS, is yet to be determined.

HHV-8 is the primary cause of several malignancies, including KS, primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD) [4]. Understanding the seroprevalence of HHV-8 is essential for assessing the burden of this virus and developing strategies to prevent the associated diseases.

Begré et al. [6] conducted a meta-analysis on this in 2016 and concluded that there was a slight gender disparity in the incidence of KS in sub-Saharan Africa (SSA). However, their findings may be outdated, since more relevant original articles on this issue have been published, we believe that the conclusion may be different now. In this meta-analysis, we not only included more English articles, but also included studies from the Asian continent in Chinese databases. Subgroup analyses were conducted separately in populations from different continents. Therefore, it is necessary to provide a more comprehensive evaluation of this issue. We conducted an updated meta-analysis to comprehensively evaluate the association between gender and HHV-8 seropositivity.

# Methods

#### Search strategy

We searched the main English and Chinese language databases. Two of our researchers (Hai-bo Gong and Shuai Zhang) conducted a literature search of the Pub-Med, EMBASE, Cochrane library, Web of Science, CNKI, and Wanfang databases for articles published before March 15, 2023. The electronic search strategy of PubMed was as follows: ((((((("Herpesvirus 8, Human"[Mesh]) OR HHV-8) OR KSHV) OR Kaposi's Sarcoma-Associated Herpesvirus) OR Kaposi's Sarcoma Associated Herpesvirus) OR Sarcoma-Associated Herpesvirus, Kaposi) OR Herpesvirus, Kaposi's Sarcoma-Associated) OR Herpesvirus, Kaposi's Sarcoma Associated) OR Human Herpesvirus 8) OR Herpesvirus, Kaposi's Sarcoma-Associated) OR Kaposi's Sarcoma-Associated Herpesviruses) OR Sarcoma-Associated Herpesviruses, Kaposi's)) AND ((((((seroprevalence) OR "Seroepidemiologic Studies"[Mesh])) OR ((Epidemiology) OR "Epidemiology"[Mesh])) OR ((incidence) OR "Incidence"[Mesh])) OR ((Prevalence) OR "Prevalence"[Mesh])).



Fig. 1 Flow diagram of literature search and screen

| _ |
|---|
| _ |

| Author                  | Year | Country       | Age         | HHV-8 tested | Sample size | HHV-8(+) |        | HHV-8(-) |      |        |      |
|-------------------------|------|---------------|-------------|--------------|-------------|----------|--------|----------|------|--------|------|
|                         |      |               | 1           | used         |             | Male     | Female |          | Male | Female |      |
| Anderson                | 2008 | USA           | Children    | EIA          | 4166        | 27       | 35     | 2026     |      |        | 2078 |
| Antony                  | 2021 | Gabon         | Adult       | IFA          | 1020        | 229      | 143    | 403      |      |        | 245  |
| Biryahwaho              | 2010 | Uganda        | Adult       | EIA          | 2715        | 712      | 793    | 526      |      |        | 684  |
| Butler (1)              | 2011 | Uganda        | Children    | EIA          | 1382        | 189      | 183    | 504      |      |        | 506  |
| Butler (2)              | 2011 | Uganda        | Adult       | EIA          | 1477        | 298      | 294    | 396      |      |        | 489  |
| Dedicoat                | 2004 | South Africa  | Children    | EIA          | 2497        | 127      | 160    | 1136     |      |        | 1074 |
| Engels                  | 2007 | NSA           | Adult       | EIA          | 13,894      | 141      | 166    | 6159     |      |        | 7428 |
| Fu                      | 2009 | China         | Adult       | EIA          | 2228        | 199      | 228    | 891      |      |        | 910  |
| Fang Yuan               | 2022 | China         | unspecified | ELISA        | 678         | 48       | 60     | 219      |      |        | 351  |
| Malope                  | 2008 | South Africa  | Adult       | EIA          | 1146        | 197      | 336    | 218      |      |        | 395  |
| Mbulaiteye              | 2003 | Tanzania      | Children    | EIA          | 361         | 125      | 122    | 88       |      |        | 102  |
| Mbulaiteye              | 2008 | Egypt         | Adult       | EIA          | 730         | 52       | 125    | 183      |      |        | 370  |
| Angela Nal-<br>woga     | 2020 | Uganda        | unspecified | ELISA        | 825         | 49       | 41     | 357      |      |        | 378  |
| Perna (1)               | 2000 | Italy         | Children    | IFA          | 319         | 6        | 11     | 159      |      |        | 140  |
| Perna (2)               | 2000 | Italy         | Children    | IFA          | 651         | 52       | 40     | 280      |      |        | 279  |
| Plancoulaine<br>(1)     | 2000 | French Guiana | Children    | IFA          | 656         | 23       | 25     | 329      |      |        | 279  |
| Plancoulaine<br>(2)     | 2000 | French Guiana | Adult       | IFA          | 681         | 58       | 71     | 251      |      |        | 301  |
| Plancoulaine<br>(1)     | 2004 | Cameroon      | Children    | IFA          | 309         | 67       | 73     | 86       |      |        | 83   |
| Plancoulaine<br>(2)     | 2004 | Cameroon      | Adult       | IFA          | 299         | 105      | 119    | 29       |      |        | 46   |
| Serraino                | 2003 | Italy         | Adult       | IFA          | 200         | 6        | 9      | 91       |      |        | 94   |
| Tedeschi                | 2006 | Sweden        | Adult       | IFA          | 516         | 39       | 36     | 218      |      |        | 223  |
| Wang                    | 2011 | China         | Adult       | EIA          | 1008        | 111      | 122    | 386      |      |        | 389  |
| Wawer                   | 2001 | Uganda        | Adult       | IFA          | 522         | 102      | 66     | 137      |      |        | 184  |
| Wen                     | 2021 | China         | unspecified | ELISA        | 1078        | 96       | 167    | 324      |      |        | 487  |
| Zheng Jun (1)           | 2017 | China         | Adult       | IFA          | 700         | 136      | 112    | 228      |      |        | 224  |
| Zheng Jun (2)           | 2017 | China         | Adult       | IFA          | 594         | 105      | 142    | 139      |      |        | 208  |
| Zhang Tiejun            | 2017 | China         | Adult       | IFA          | 1583        | 96       | 66     | 887      |      |        | 534  |
| Cao Yifei               | 2014 | China         | Children    | IFA          | 178         | 47       | 39     | 61       |      |        | 31   |
| Angela Nal-<br>woga (1) | 2019 | Uganda        | unspecified | ELISA        | 1571        | 646      | 561    | 155      |      |        | 209  |

| Table 1 (con            | ntinued)          |                   |                    |                    |             |          |        |          |          |     |  |
|-------------------------|-------------------|-------------------|--------------------|--------------------|-------------|----------|--------|----------|----------|-----|--|
| Author                  | Year              | Country           | Age                | HHV-8 tested       | Sample size | HHV-8(+) |        | HHV-8(-) |          |     |  |
|                         |                   |                   |                    | usea               |             | Male     | Female | Mã       | ile Fema | U   |  |
| Angela Nal-<br>woga (2) | 2019              | Uganda            | unspecified        | ELISA              | 1310        | 641      | 450    | 103      |          | 116 |  |
| Kay L. Crabtree         | 2017              | Zambia            | Children           | IFA                | 270         | 65       | 72     | 76       |          | 57  |  |
| Ryoko Awa-<br>zawa      | 2017              | Japan             | Adult              | ELISA              | 1132        | 97       | 77     | 489      |          | 469 |  |
| Yuan<br>Huangbo         | 2018              | China             | Adult              | IFA                | 594         | 105      | 142    | 139      |          | 208 |  |
| Zhang xin               | 2022              | China             | Adult              | IFA                | 721         | 68       | 106    | 208      |          | 339 |  |
| Zhang ying (1)          | 2013              | China             | unspecified        | ELISA              | 1008        | 22       | 21     | 529      |          | 436 |  |
| Zhang ying (2)          | 2013              | China             | unspecified        | ELISA              | 100         | 20       | 20     | 402      |          | 527 |  |
| Zhang ying (3)          | 2013              | China             | unspecified        | ELISA              | 882         | 28       | 21     | 472      |          | 361 |  |
| Fang yuan               | 2017              | China             | unspecified        | ELISA              | 1000        | 87       | 103    | 293      |          | 517 |  |
| Fang qin                | 2006              | China             | unspecified        | ELISA              | 560         | 18       | 11     | 299      |          | 232 |  |
| Zhu ye                  | 2010              | China             | unspecified        | ELISA              | 1281        | 38       | 55     | 643      |          | 545 |  |
| He miao                 | 2014              | China             | Adult              | IFA                | 171         | 58       | 29     | 42       |          | 42  |  |
| ElA Enzyme imm          | unoassay, IFA lmm | unofluorescence a | assay, ELISA Enzym | e linked immunosor | bent assay  |          |        |          |          |     |  |

Page 4 of 14

# Inclusion and exclusion criteria

We collected data from cross-sectional studies on HHV-8 seroprevalence worldwide. The recruited participants in the included studies were representative of the general local population. The following information was extracted from the included studies: proportion of seropositive individuals by sex, race, and age. Therefore, studies conducted on blood donors, hospital-based studies, and studies conducted on specific populations, such as men who have sex with men, patients with solid organ transplants, HIV-positive individuals, those using intravenous (IV) drugs, or those who were incarcerated, were excluded.

#### **Data extraction**

Two researchers, Gong Haibo and Zhang Shuai, independently extracted all the information from the included literature, including the authors, year of publication, country and region, total number of participants, number of men, number of women, frequency of seropositivity, frequency of seronegativity, age composition of the participants (children or adults), and number of seropositive individuals. Methods for the detection of HHV-8 and antibodies used in the detection process were also recorded. In case of disagreement, the two authors discussed the issue and submitted it to a third author for adjudication.

| Suay<br>ID                                     | OR (95% CI)       | Events,<br>Exposed group | Events,<br>Non-exposed group | %<br>We |
|--|-------------------|--------------------------|------------------------------|---------|
| Anderson (2008)                                | 0.79 (0.48, 1.31) | 27/2053                  | 35/2113                      | 1.6     |
| Angela Nalwoga (1) (2019)                      | 1.55 (1.23, 1.97) | 646/801                  | 561/770                      | 3.8     |
| Angela Nalwoga (2) (2019)                      | 1.60 (1.20, 2.15) | 641/744                  | 450/566                      | 3.1     |
| Antony (2021)                                  | 0.97 (0.75, 1.27) | 229/632                  | 143/388                      | 3.5     |
| Biryahwaho (2010)                              | 1.17 (1.00, 1.36) | 712/1238                 | 793/1477                     | 4.9     |
| Butler (1) (2011)                              | 1.04 (0.82, 1.32) | 189/693                  | 183/689                      | 3.7     |
| Butler (2) (2011)                              | 1.25 (1.02, 1.54) | 298/694                  | 294/783                      | 4.1     |
| Cao Yifei (2014)                               | 0.61 (0.33, 1.12) | 47/108                   | 39/70                        | 1.2     |
| Dedicoat (2004)                                | 0.75 (0.59, 0.96) | 127/1263                 | 160/1234                     | 3.6     |
| Engels (2007)                                  | 1.02 (0.82, 1.29) | 141/6300                 | 166/7594                     | 3.9     |
| Fang din (2006)                                | 1.27 (0.59, 2.74) | 18/317                   | 11/243                       | 0.8     |
| Fang yuan (2017)                               | 1 49 (1 08, 2 05) | 87/380                   | 103/620                      | 2.8     |
| Fang Yuan (2022)                               | 1 28 (0.85, 1.94) | 48/267                   | 60/411                       | 2.0     |
|  | 0.89 (0.72, 1.10) | 199/1090                 | 228/1138                     | 4 1     |
| He miso (2014)                                 | 2 00 (1 08 3 71)  | 58/100                   | 20/71                        | 1.1     |
| Kay L Crahtree (2017)                          | 0.68 (0.42, 1.09) | 65/141                   | 72/129                       | 1.1     |
|  | 1.06 (0.83, 1.35) | 197/415                  | 336/731                      | 3.7     |
|  | 1.10 (0.83, 1.33) | 135/212                  | 122/224                      | 3.1     |
| Mbulaiteye (2003)                              | 0.84 (0.58, 1.22) | 52/225                   | 122/224                      | 2.5     |
| Nelvinge (2000)                                | 1.27 (0.82, 1.06) | 40/406                   | 120/485                      | 4.9     |
| Ratwoga (2020)                                 | 1.27 (0.02, 1.96) | 49/400                   | 41/419                       | 1.8     |
| Perna (1) (2000)                               | 1.20 (0.23, 1.73) | 5/100                    | 10/210                       | 1.0     |
| Plenosulaise(1) (2000)                         | 0.78 (0.43, 1.41) | 32/352                   | 40/319                       | 1.9     |
| Plancoulaine(1) (2000)                         | 0.78 (0.43, 1.41) | 23/352                   | 20/004                       | 1.2     |
| Plancoulaine(1) (2004)                         | 0.09 (0.57, 1.59) | 67/155                   | 73/130                       | 1.8     |
| Plancoulaine(2) (2000)                         | 0.98 (0.67, 1.44) | 50/309                   | 11/3/2                       | 2.3     |
| Piałcoulaine(2) (2004)                         | 1.40 (0.62, 2.39) | 105/134                  | 77/640                       | 1.4     |
|  | 1.21 (0.67, 1.67) | 97/500                   | 777540                       | 2.0     |
| Tertereki (2003)                               | 1.55 (0.53, 4.53) | 9/100                    | 6/100                        | 0.4     |
|  | 1.11 (0.68, 1.81) | 39/257                   | 36/259                       | 1.0     |
| Wang (2011)                                    | 0.92 (0.68, 1.23) | 111/497                  | 122/511                      | 3.1     |
| Wawer (2001)                                   | 1.38 (0.97, 1.97) | 102/239                  | 99/283                       | 2.5     |
| Vien (2021)                                    | 0.86 (0.65, 1.15) | 96/420                   | 167/654                      | 3.2     |
| Yuan Huangbo (2018)                            | 1.11 (0.79, 1.54) | 105/244                  | 142/350                      | 2.7     |
|  | 0.88 (0.63, 1.22) | 96/983                   | 66/600                       | 2.7     |
| Zhang xin (2022)                               | 1.05 (0.74, 1.48) | 68/276                   | 106/445                      | 2.6     |
| Znang ying (1) (2013)                          | 0.86 (0.47, 1.59) | 22/551                   | 21/457                       | 1.1     |
|  | 1.31 (0.70, 2.47) | 20/422                   | 20/547                       | 1.1     |
| Zhang ying (3) (2013)                          | 1.02 (0.57, 1.83) | 28/500                   | 21/382                       | 1.2     |
| Zheng Jun (1) (2017)                           | 1.19 (0.87, 1.63) | 136/364                  | 112/336                      | 2.9     |
| Zheng Jun (2) (2017)                           | 1.11 (0.79, 1.54) | 105/244                  | 142/350                      | 2.7     |
| Zhu ye (2010)                                  | 0.59 (0.38, 0.90) | 38/681                   | 55/600                       | 2.0     |
| Overall (I-squared = 44.8%, p = 0.001)         | 1.07 (0.99, 1.15) | 5341/25902               | 5482/28052                   | 10      |
| NOTE: Weights are from random effects analysis |                   |                          |                              |         |

Fig. 2 Forest plot of all included population worldwide





Fig. 3 Subgroup analysis of all included studies worldwide stratified by age. a, Subgroup analysis of adult population included in all studies worldwide. b, Subgroup analysis of child population included in all studies worldwide

#### Statistical analyses

This meta-analysis was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines [7]. Both the Q-statistical test and  $I^2$  test were used to calculate between-study heterogeneity [8, 9]. In general, random- and fixed-effects models were used to combine the data in the presence (p < 0.1,  $I^2 > 40\%$ ) or absence of heterogeneity (p > 0.1,  $I^2 < 40\%$ ). The results of  $I^2$  statistic and Q statistic are often inconsistent in the actual calculation process. Because the number of studies in different subgroup analysis varies greatly, I<sup>2</sup> statistic results will not change with the change of the number of studies, when in this situation, we used the I<sup>2</sup> statistic to determine whether the heterogeneity was significant. Stata version 12.0 (StataCorp LP, College Station, TX, USA) was used to generate the forest and Egger's plots.

# Results

#### Number of eligible, included, and excluded studies

Using our search strategy, we searched six different databases, including the four main English language databases, PubMed, EMBASE, Cochrane and the Web of Science, and the two main Chinese language databases, CNKI and Wanfang. We then eliminated duplicate studies, and further eliminated abstracts, case reports, reviews, and other irrelevant studies that were not related to the content of this issue. Ultimately, 33 articles were included, of which 28 were in English and 5 in Chinese [10–42]. The literature identification process is illustrated in Fig. 1.

### **Characteristics of included studies**

Forty-one study groups from 33 articles included 25,902 male and 28,052 female participants. Detailed information about each study is presented in Table 1. The studies were from five continents: 15 (45%) from Asia, 12 (36%) from Africa, 2 (6%) from North America, 1 (3%) from South America, and 3 (9%) from the Europe. Of these, 10



Fig. 4 Subgroup analysis of population from Sub-Saharan Africa



b



Fig. 5 Subgroup analysis of populations from Sub-Saharan Africa stratified by age. **a**, Subgroup analysis of adult population included in studies from sub-Saharan Africa. **b**, Subgroup analysis of child population included in studies from sub-Saharan Africa



b



Fig. 6 Subgroup analysis of populations from other continents. **a**, Subgroup analysis of population from Asia. **b**, Subgroup analysis of population from Europe and America

studies included only children and 20 studies included only adults. The ages of the participants in the remaining 11 studies were unspecified.

#### Meta-analysis results

For the total included population from all over the world, random-effects models analyses showed no significant difference between gender and HHV-8 seropositivity (OR: 1.07, 95% CI: 0.99–1.15; Fig. 2), while the fixed-effects models showed that there was a significant association between gender and HHV-8 seropositivity (OR: 1.07, 95% CI: 1.02–1.13; Appendix.1). Because of some degree of heterogeneity between studies ( $I^2$ =44.8%, p=0.001), we finally selected the random-effects model results as the final calculation. For the total included adult population, there was a significant association between male gender and HHV-8

seropositivity (OR: 1.08, 95% CI: 1.01–1.15; Fig. 3a); however, no such association was found in the child population (OR: 0.90, 95% CI: 0.79–1.01; Fig. 3b).

In the SSA region, For the total population  $(I^2 = 58.2\%, p = 0.002)$ , the heterogeneity between studies was large enough so that we choose the random effect model for calculation. The results showed no significant difference (OR: 1.11, 95% CI: 0.99–1.25, Fig. 4). While using a fixed-effect model, it was found that male gender was associated with HHV-8 seropositivity in the total population (OR 1.13, 95% CI 1.05–1.21; Appendix.2). In the adult population subgroup (OR: 1.15, 95% CI: 1.05–1.26; Fig. 5a), but not in children (OR: 0.90, 95% CI: 0.78–1.03; Fig. 5b).

For other continents in the world, the results also showed that no statistically significant difference was observed (Asian region, OR: 1.03, 95% CI: 0.92–1.16;



Fig. 7 Publication bias for included studies worldwide. a, Publication bias for all included studies worldwide. b, Publication bias of adult population studies included worldwide. c, Publication bias of child population studies included worldwide

Fig. 6a; European and American population, OR: 1.01, 95%CI: 0.87–1.17; Fig. 6b).

#### Sensitivity analysis and study bias

We removed the included studies individually to test the robustness and reliability of the results. The significance of the pooled ORs and 95% CIs did not change, indicating the stability of the results.

We used Egger's test to calculate the publication bias of the included studies in each subgroup analysis, and these results are shown in Figs. 7, 8, and 9. All the *p*-values of Egger's test were > 0.1, indicating that there was no publication bias between the included studies in all group analyses. Including the total population from all over the world (p=0.504, Fig. 7a); adult-only population from all over the world (p=0.455, Fig. 7b); child-only population from all over the world (p=0.489, Fig. 7c); total SSA population (p=0.477, Fig. 8a); adult-only population from SSA (p=0.939, Fig. 8b); child-only population from SSA (p=0.730, Fig. 8c); Asian population (p=0.531, Fig. 9a); and European and American population (p=0.774, Fig. 9b).

# Discussion

This is an updated meta-analysis based on the work of Begré et al. [6]. To date, this meta-analysis is the most comprehensive. Our results suggested that HHV-8 infection is slightly more common in men than in women among the adult SSA population as well as the adult population from all over the world. However, in children across all populations, not just SSA, there were no results suggesting that boys were more likely to be infected with HHV-8 than girls. These results suggest that the male gender vulnerability of HHV-8 infection may not be related to genetic background, but to living habits and environmental factors in the region. The importance of the results from the fixed-effects model analysis of all included populations in SSA and all over the world should not be overlooked; we believe that when the quality of research is sufficiently standardized and the number of quantity researchers is large enough, we can apply the fixed-effects model and may conclude that there is a statistical difference.

The higher incidence of KS in men than in women may be attributed to a combination of immune system



Fig. 8 Publication bias for included studies in Sub-Saharan Africa. a, Publication bias for all included studies in SSA. b, Publication bias of adult population studies included in SSA. c. Publication bias of child population studies included in SSA



Fig. 9 Publication bias for included studies in other continents. a, Publication bias for all included studies in Asia. b, Publication bias for all included studies in Europe and Americas

differences; hormonal, viral and genetic factors; and high-risk behaviors. Understanding these factors is crucial to developing better strategies for the prevention, early detection, and treatment of KS. The sero-epidemiologic distribution of HHV-8 may play a role in the pathogenesis of KS. It is probably not a coincidence that the results for the SSA adult population were consistent with those for all included adult population worldwide. However, this remains unclear because, clinically, far more male cases than female cases of KS have been encountered. Yet our results showed that men have only a weak predisposition to HHV-8 infection compared with women, since none of the ORs were very large. The statistical differences observed in our study were only slightly significant. Therefore, the higher number of men affected by KS compared to women is likely multifactorial, involving a combination of biological, behavioral, and social factors. The extent to which infection with the Kaposi's sarcoma-associated herpesvirus contributes to this phenomenon requires further research. There may be additional patterns underlying these results that remain to be understood.

This study has several limitations. Firstly, the male gender predominance in KS may have multifactorial causes. This study only examines this issue from the perspective of HHV-8 infection. Other contributing factors could include variances in immune system responses between men and women, hormonal influences, genetic predispositions, and gender-related behaviors. However, their exact impacts and roles remain unclear. Secondly, this study only included papers published in English and Chinese, excluding those published in other languages, which may introduce selection bias. Moreover, variations in technical methods, reagent manufacturers, age determination criteria for children in subgroup analyses, and the stringency of study population screening across different investigations could also introduce biases, thereby affecting the final outcomes. Thirdly, while we aimed to include all relevant studies on the global seroprevalence of HHV-8, the number of studies included was relatively limited. Further research with larger sample sizes and more comprehensive analyses is warranted.

#### Conclusion

Adult populations from Sub-Saharan Africa (SSA), similar to adult populations worldwide, are more likely to test positive for HHV-8 seropositivity than women. However, no significant differences were observed among children from the same regions. These sero-epidemiological patterns of KSHV may help explain the higher prevalence of Kaposi's Sarcoma (KS) in men compared to women.

#### Abbreviations

- KS Kaposi's sarcoma
- PEL Primary effusion lymphoma
- SSA Sub-Saharan African

## Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12879-024-09346-5.



#### Authors' contributions

Gong HB proposed the idea for this study and completed the first draft of the paper. Chen Jing reviewed and revised the manuscript draft and provided valuable suggestions. Gong HB and Zhang Shuai independently performed the process of literature retrieval and data extraction, and Dou JF performed the data calculation and drawing.

#### Funding

This work was funded by the Joint Project of Henan Medical Science and Technology Research Program (LHGJ20210030).

#### Availability of data and materials

All data generated or analyzed during this study are included in this published article.

#### Declarations

#### Ethics approval and consent to participate

All analyses in this study relied on previously published literature and public databases, and no human participants were included. Therefore, this study did not require ethical approval or patient consent.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

#### Received: 22 October 2023 Accepted: 23 April 2024 Published online: 29 April 2024

#### References

- Etemad SA, Dewan AK. Kaposi's Sarcoma Updates. Dermatol clin. 2019;37:505–17.
- Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi's sarcoma. Nat rev Dis primers. 2019;5:9.
- Sternbach G, Varon J. Moritz Kaposi: idiopathic pigmented sarcoma of the skin. J Emerg Med. 1995;13:671–4.
- Lange P, Damania B. Kaposi's Sarcoma-Associated Herpesvirus (KSHV). Trends Microbiol. 2020;28:236–7.
- Barrett L, Dai L, Wang S, Qin Z. Kaposi's sarcoma-associated herpesvirus and extracellular vesicles. J Med virol. 2021;93:3294–9.
- Begré L, Rohner E, Mbulaiteye SM, Egger M, Bohlius J. Is human herpesvirus 8 infection more common in men than in women? Systematic review and meta-analysis. Int J Cancer. 2016;139:776–83.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med. 2009;6:e1000097.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
- Anderson LA, Li Y, Graubard BI, Whitby D, Mbisa G, Tan S, Goedert JJ, Engels EA. Human herpesvirus 8 seroprevalence among children and adolescents in the United States. Pediatr Infect Dis J. 2008;27:661–4.
- Biryahwaho B, Dollard SC, Pfeiffer RM, Shebl FM, Munuo S, Amin MM, Hladik W, Parsons R, Mbulaiteye SM. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative populationbased sample in Uganda. J Infect Dis. 2010;202:1347–53.
- Butler LM, Were WA, Balinandi S, Downing R, Dollard S, Neilands TB, Gupta S, Rutherford GW, Mermin J. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis. 2011;203:625–34.
- Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B, Page T, Casabonne D, Gilks CF, Cassol SA, Whitby D, Schulz TF. Mother-tochild transmission of human herpesvirus-8 in South Africa. J Infect Dis. 2004;190:1068–75.
- Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, Mbisa G, Cohn S, Whitby D, Goedert JJ. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007;196:199–207.
- Fu B, Sun F, Li B, Yang L, Zeng Y, Sun X, Xu F, Rayner S, Guadalupe M, Gao SJ, Wang L. Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Xinjiang. China J Med Virol. 2009;81:1422–31.
- Malope BI, MacPhail P, Mbisa G, MacPhail C, Stein L, Ratshikhopha EM, Ndhlovu L, Sitas F, Whitby D. No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. AIDS (London, England). 2008;22:519–26.

- Mbulaiteye SM, Pfeiffer RM, Dolan B, Tsang VC, Noh J, Mikhail NN, Abdel-Hamid M, Hashem M, Whitby D, Thomas Strickland G, Goedert JJ. Seroprevalence and risk factors for human herpesvirus 8 infection, rural Egypt. Emerg Infect Dis. 2008;14:586–91.
- Mbulaiteye SM, Pfeiffer RM, Whitby D, Brubaker GR, Shao J, Biggar RJ. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis. 2003;187:1780–5.
- Perna AM, Bonura F, Vitale F, Viviano E, Di Benedetto MA, Ajello F, Villafrate MR, Prestileo T, Mancuso S, Goedert JJ, Romano N. Antibodies to human herpes virus type 8 (HHV8) in general population and in individuals at risk for sexually transmitted diseases in Western Sicily. Int J Epidemiol. 2000;29:175–9.
- Plancoulaine S, Abel L, Trégouët D, Duprez R, van Beveren M, Tortevoye P, Froment A, Gessain A. Respective roles of serological status and blood specific antihuman herpesvirus 8 antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. Cancer Res. 2004;64:8782–7.
- Plancoulaine S, Abel L, van Beveren M, Trégouët DA, Joubert M, Tortevoye P, de Thé G, Gessain A. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet (London, England). 2000;356:1062–5.
- Serraino D, Corona RM, Giuliani M, Farchi F, Sarmati L, Uccella I, Andreoni M, Rezza G. Infection with human herpesvirus type 8 and kaposi's sarcoma in a central Italian area formerly endemic for malaria. Infection. 2003;31:47–50.
- Tedeschi R, Bidoli E, Agren A, Hallmans G, Wadell G, De Paoli P, Dillner J. Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Västerbotten County. Sweden J Med Virol. 2006;78:372–8.
- Wang H, Liu J, Dilimulati, Li L, Ren Z, Wen H, Wang X. Seroprevalence and risk factors of Kaposi's sarcoma-associated herpesvirus infection among the general Uygur population from south and north region of Xinjiang, China. Virol J. 2011;8:539.
- 25. Wawer MJ, Eng SM, Serwadda D, Sewankambo NK, Kiwanuka N, Li C, Gray RH. Prevalence of Kaposi's sarcoma-associated herpesvirus compared with selected sexually transmitted diseases in adolescents and young adults in rural Rakai District. Uganda Sex Transm Dis. 2001;28:77–81.
- Zheng J, Yang Y, Cui M, Shu ZJ, Han LL, Liu ZQ, Wood C, Zhang T, Zeng Y. Prevalence of Kaposi's sarcoma-associated herpesvirus in Uygur and Han populations from the Urumqi and Kashgar regions of Xinjiang. China Virol Sin. 2017;32:396–403.
- Zhang T, Liu Z, Wang J, Minhas V, Wood C, Clifford GM, He N, Franceschi S. Seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus among HIV-negative people in China. Infect Agent Cancer. 2017;12:32.
- Cao Y, Minhas V, Tan X, Huang J, Wang B, Zhu M, Gao Y, Zhao T, Yang L, Wood C. High prevalence of early childhood infection by Kaposi's sarcoma-associated herpesvirus in a minority population in China. Clin Microbiol Infect. 2014;20:475–81.
- 29. Nalwoga A, Webb EL, Chihota B, Miley W, Walusimbi B, Nassuuna J, Sanya RE, Nkurunungi G, Labo N, Elliott AM, Cose S, Whitby D, et al. Kaposi's sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands. PLoS Negl Trop Dis. 2019;13:e0007776.
- Crabtree KL, Wojcicki JM, Minhas V, Kankasa C, Mitchell C, Wood C. Association of Household Food- and Drink-Sharing Practices With Human Herpesvirus 8 Seroconversion in a Cohort of Zambian Children. J Infect Dis. 2017;216:842–9.
- Awazawa R, Utsumi D, Katano H, Awazawa T, Miyagi T, Hayashi K, Matori S, Uezato H, Takahashi K. High Prevalence of Distinct Human Herpesvirus 8 Contributes to the High Incidence of Non-acquired Immune Deficiency Syndrome-Associated Kaposi's Sarcoma in Isolated Japanese Islands. J Infect Dis. 2017;216:850–8.
- Yuan H, Liu Z, Wu X, Fang Q, Zheng J, Zeng Y, Zhang T. Social behavioral correlates of Kaposi's sarcoma-associated herpesvirus infection among Han and Uygur populations in Xinjiang. China J Med Virol. 2019;91:457–62.
- Zhang X, Fang Q, Zhu S, Wu X, Yuan H, Liu Z, Xu Y, Chen T, Zeng Y, Zhang T. Environmental risk factors and genetic markers of Kaposi's sarcomaassociated herpesvirus infection among Uygur population in Xinjiang. China J Med Virol. 2022;94:2755–65.

- Fang Y, Li W, Zhang Y, Zhou C, Wu H, Zhang Y, Dai T, Wang J, Wang L, Chen T, Zhu Y, Wang L. Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Jiuquan area. China J Med Virol. 2022;94:6016–22.
- 35. Mamimandjiami Al, Mouinga-Ondémé A, Ramassamy JL, Djuicy DD, Afonso PV, Mahé A, Lekana-Douki JB, Cassar O, Gessain A. Epidemiology and Genetic Variability of HHV-8/KSHV among Rural Populations and Kaposi's Sarcoma Patients in Gabon, Central Africa. Review of the Geographical Distribution of HHV-8 K1 Genotypes in Africa. Viruses 2021;13.
- Nalwoga A, Nakibuule M, Marshall V, Miley W, Labo N, Cose S, Whitby D, Newton R. Risk Factors for Kaposi's Sarcoma-Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda. Clin Infect Dis. 2020;71:1055–62.
- Wen Z, Li W, Fang Y, Zhou C, Lin K, Wu H, Zhang Y, Zhu Y, Xu X, Zeng Y, Lu B, Wang L. Prevalence and Risk Factors of Kaposi's Sarcoma-Associated Herpesvirus Infection among Han and Uygur Populations in Xinjiang, China. Can J Infect Dis Med Microbiol. 2021;2021:2555865.
- Zhang Y. Epidemiological study of Kaposi's sarcoma-associated herpesviruses in Anhui province [D]. Anhui Medical University, 2013.
- Fang Yuan, Xu Changqing, Zhou Chang, et al. Serological analysis of Kapossarcoma-associated herpesvirus infection in general population in Dunhuang, Gansu Province. J Anhui Med University 2017 (5): 697-700.
- Fang Q, Liu J, Bai ZQ, et al. Serological analysis of Kaposi's sarcomaassociated herpesvirus infection in general population in Hubei province. Virologica Sinica. 2006;02:97–101.
- Ye Z, Wang Linding Fu, Bishi. Serological survey of Kaposi's sarcomaassociated herpesvirus infection in general population in Jingzhou, Hubei Province. J Mathematical Science and Medicine. 2010;23(03):328–30.
- 42. He M. The prevalence and risk factors of KSHV infection in children in Xinjiang. Shihezi University, 2014.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.